Alvotech
NASDAQ:ALVODrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $1.62B
- Beta
- 0.21
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.24
Volume 1.56M
Average 0.65M
ALVO Total Non-current Liabilities
All obligations due after more than one year.
AlvotechNASDAQ: ALVO
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 12.6% from a year ago
Total non-current liabilities stood at $1.44B at the end of Q1 FY2026, up 12.6% from a year earlier and down 1.6% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.
Context
- Total non-current liabilities amounted to 101.6% of total assets at the end of Q1 FY2026, down 1.3 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +12.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.47B USD
- Year-over-year change
- +1.9%
- 4-year CAGR
- +23.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.47B | +1.9% |
| FY2024 | 2024-12-31 | 1.44B | -11.2% |
| FY2023 | 2023-12-31 | 1.62B | +32.3% |
| FY2022 | 2022-12-31 | 1.23B | +97.1% |
| FY2021 | 2021-12-31 | 621.75M | — |
Total Non-current Liabilities vs competitors
How ALVO compares with its peers on the latest reported figures
- ALVO's Mar 2026 total non-current liabilities of $1.44B is the 7th highest of the 11 companies compared; the peer median is $3.63B.
- Its year-over-year change of +12.6% is the 4th highest of 11, against a peer median of -1.6%.
- Total non-current liabilities amounts to 101.6% of total assets for ALVO, versus a peer median of 48.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $58.45B | -2.6% | +7.2% | 61.1% | |
| Jun 2026 | $16.45B | -23.3% | -6.8% | 41.3% | |
| Sep 2026 | $9.56B | -4.1% | +1.4% | 71.3% | |
| Jun 2026 | $9.32B | +24.1% | -0.3% | 29.1% | |
| Jun 2026 | $4.49B | -2.7% | +13.1% | 10.8% | |
| Jun 2026 | $2.78B | +17.5% | -0.6% | 73.5% | |
| Mar 2026 | $1.44B | +12.6% | +6.2% | 101.6% | |
| Mar 2026 | $904.56M | -0.6% | +18.8% | 54.8% | |
| Mar 2026 | $710.29M | +5.1% | +79.3% | 43.1% | |
| Mar 2026 | $299.75M | +147.6% | +31.1% | 71.4% | |
| Mar 2026 | $22.92M | -33.1% | +71.0% | 23.5% | |
| Peer median (excluding ALVO) | $3.63B | -1.6% | +10.2% | 48.9% | |
Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17.56M | 66.43M | 11.16M | 51.43M | 172.36M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 53.88M | 71.39M | 87.22M | 251.72M | 153.79M |
| Inventory | 39.06M | 71.47M | 74.43M | 127.89M | 220.05M |
| Other Current Assets | 0 | 851K | 0 | 0 | 0 |
| Total Current Assets | 119.82M | 230.74M | 194.84M | 455.02M | 574.02M |
| Property, Plant & Equipment (Net) | 205.33M | 268.1M | 356.58M | 409.74M | 356.4M |
| Goodwill | 12.37M | 11.64M | 12.06M | 11.33M | 12.84M |
| Intangible Assets | 21.51M | 25.65M | 19.08M | 20.62M | 81.83M |
| Long-term Investments | 55.31M | 48.57M | 18.49M | 22.71M | 122.93M |
| Tax Assets | 170.42M | 209.5M | 309.81M | 298.36M | 192.21M |
| Other Non-current Assets | 13.23M | 34.25M | 39.23M | 3.62M | 146.87M |
| Total Non-current Assets | 478.16M | 597.71M | 755.25M | 766.38M | 913.08M |
| Total Assets | 597.98M | 828.44M | 950.09M | 1.22B | 1.49B |
| Account Payables | 28.59M | 49.19M | 80.56M | 67.13M | 126.12M |
| Short-term Debt | 2.77M | 19.92M | 38.03M | 32.7M | 36.92M |
| Tax Payables | 841K | 934K | 925K | 204K | 1.04M |
| Deferred Revenue | 29.69M | 36.92M | 59.18M | 15.98M | 30.36M |
| Other Current Liabilities | 5.26M | 17.46M | 34.5M | 6.63M | 13.7M |
| Total Current Liabilities | 111.84M | 167.29M | 260.95M | 193.4M | 304.08M |
| Long-term Debt | 398.14M | 744.65M | 922.13M | 1.04B | 1.26B |
| Deferred Tax Liabilities | 150K | 309K | 53K | 1.81M | 7.87M |
| Deferred Revenue (Non-current) | 44.84M | 57.02M | 73.26M | 80.72M | 5.5M |
| Other Non-current Liabilities | 63.77M | 388.22M | 520.55M | 210.22M | 53.99M |
| Total Non-current Liabilities | 621.75M | 1.23B | 1.62B | 1.44B | 1.47B |
| Total Liabilities | 733.59M | 1.39B | 1.88B | 1.63B | 1.77B |
| Common Stock | 135K | 2.13M | 2.28M | 2.83M | 2.93M |
| Retained Earnings | (1.14B) | (1.65B) | (2.21B) | (2.44B) | (2.41B) |
| Accumulated OCI | 4.67M | 29.14M | 41.38M | 15.05M | 16.68M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (135.61M) | (564.42M) | (932.49M) | (412.77M) | (284.49M) |
| Total Debt | 523.05M | 805.1M | 1.08B | 1.19B | 1.45B |
| Net Debt | 505.5M | 738.68M | 1.06B | 1.14B | 1.28B |
Alvotech
NASDAQ:ALVO
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.